B-cell Lymphoma Pipeline Insight 2024, with Comprehensive Insights for 295+ Companies and 300+ Pipeline Drugs - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "B-cell Lymphoma - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.

This "B-cell Lymphoma- Pipeline Insight, 2024" report provides comprehensive insights about 295+ companies and 300+ pipeline drugs in B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence B-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve B-cell Lymphoma.

B-cell Lymphoma Emerging Drugs Chapters

This segment of the B-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

B-cell Lymphoma: Therapeutic Assessment

This segment of the report provides insights about the different B-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in B-cell Lymphoma

There are approx. 295+ key companies which are developing the therapies for B-cell Lymphoma. The companies which have their B-cell Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Denovo BioPharma.

The report covers 300+ products under different phases of clinical development like:

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular
• Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

B-cell Lymphoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses B-cell Lymphoma therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging B-cell Lymphoma drugs.

B-cell Lymphoma Report Insights

• B-cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

B-cell Lymphoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing B-cell Lymphoma drugs?
• How many B-cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of B-cell Lymphoma?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the B-cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for B-cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Lisocabtagene maraleucel
• Hoffmann-La Roche
• Nektar Therapeutics
• Miltenyi Biomedicine
• AVM Biotechnology
• Lin BioScience
• Incyte Corporation
• ADC Therapeutics
• Genor Biopharma
• Beijing InnoCare Pharma Tech Co., Ltd.
• CARGO Therapeutics
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• SystImmune
• LIBO PHARMA
• Abclon
• BeiGene
• Cellectis
• Iovance Biotherapeutics, Inc.
• Guangzhou Excelmab
• Y-mAbs Therapeutics
• TG Therapeutics
• Sutro Biopharma
• AbbVie
• Aleta Biotherapeutics
• Janssen Research & Development
• Lantern Pharma
• Beijing Immunochina Medical Science and Technology
• Bantam Pharmaceutical
• Lin Bioscience
• SFA Therapeutics
• neoX Biotech
• March Biosciences
• HUTCHMED

Key Products

• Bristol Myers Squibb
• Glofitamab
• NKTR-255
• Zamtocabtagene autoleucel
• MB-CART20.1
• AVM0703
• LBS-007
• Parsaclisib
• Loncastuximab tesirine
• GB-241
• ICP-248
• CRG-022
• TQB3702
• GNC-038
• NM-IL-12
• AT101
• BGB-16673
• UCART20x22
• IOV-2001
• EX103
• CD38-SADA
• TG-1801
• STRO-001
• ABBV-319
• ALETA-001
• JNJ-80948543
• LP-284
• INS19 CAR-T Cells
• BTM 3566
• LBS-007
• SFA-001
• NXD07
• MB-105
• HMPL A067

For more information about this clinical trials report visit https://www.researchandmarkets.com/r/qxd94m

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.